Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 40Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 851Lung Neoplasms 575Small Cell Lung Carcinoma 164Colorectal Neoplasms 130Breast Neoplasms 104Melanoma 100Neoplasms 91Ovarian Neoplasms 89Neoplasm Metastasis 82Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 68Stomach Neoplasms 59Carcinoma, Renal Cell 54Head and Neck Neoplasms 53Esophageal Neoplasms 48Triple Negative Breast Neoplasms 47Endometrial Neoplasms 47Prostatic Neoplasms 45Uterine Cervical Neoplasms 41Colonic Neoplasms 40Urinary Bladder Neoplasms 39Mesothelioma 38Carcinoma, Hepatocellular 35Mesothelioma, Malignant 34Brain Neoplasms 30Sarcoma 28Carcinoma, Transitional Cell 28Adenocarcinoma of Lung 28Lung Diseases 24Disease 24

Interventions

amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Thoracic × 90 days × Clear all
NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

ORIC Pharmaceuticals

Phase 1 Recruiting
76 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡